Thomas Hofstaetter Net Worth

The estimated Net Worth of Thomas Hofstaetter is at least $424 Thousand dollars as of 18 March 2015. Thomas Hofstaetter owns over 70,000 units of Geron stock worth over $423,916 and over the last 14 years Thomas sold GERN stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Thomas Hofstaetter GERN stock SEC Form 4 insiders trading

Thomas has made over 2 trades of the Geron stock since 2015, according to the Form 4 filled with the SEC. Most recently Thomas exercised 70,000 units of GERN stock worth $88,200 on 18 March 2015.

The largest trade Thomas's ever made was exercising 70,000 units of Geron stock on 18 March 2015 worth over $88,200. On average, Thomas trades about 11,667 units every 0 days since 2010. As of 18 March 2015 Thomas still owns at least 96,564 units of Geron stock.

You can see the complete history of Thomas Hofstaetter stock trades at the bottom of the page.

What's Thomas Hofstaetter's mailing address?

Thomas's mailing address filed with the SEC is C/O GERON CORPORATION, 149 COMMONWEALTH DRIVE, SUITE 2070, MENLO PARK, CA, 94025.

Insiders trading at Geron

Over the last 21 years, insiders at Geron have traded over $2,393,273 worth of Geron stock and bought 340,678 units worth $567,384 . The most active insiders traders include John A Scarlett, Daniel Bradbury, and Stephen Rosenfield. On average, Geron executives and independent directors trade stock every 93 days with the average trade being worth of $587,812. The most recent stock trade was executed by Andrew J Grethlein on 8 July 2024, trading 674,348 units of GERN stock currently worth $1,159,879.

What does Geron do?

we are a biopharmaceutical company developing first-in-class therapies for cancer. imetelstat, a novel, first-in-class telomerase inhibitor, is our product candidate in clinical development. telomerase enables cancer cells to maintain telomere length, which provides them with the capacity for limitless cellular replication. imetelstat is a potent and specific inhibitor of telomerase. based on clinical data we obtained in late 2012, we may develop imetelstat to treat one or more hematologic myeloid malignancies such as myelofibrosis, or mf, myelodysplastic syndromes, or acute myelogenous leukemia.

Complete history of Thomas Hofstaetter stock trades at Geron

Geron executives and stock owners

Geron executives and other stock owners filed with the SEC include:

• John Scarlett,
  Chairman of the Board, President, Chief Executive Officer
• Aleksandra Rizo,
  Executive Vice President, Chief Medical Officer
• Dr. John A. Scarlett,
  CEO, Pres & Chairman
• Stephen Rosenfield,
  Executive Vice President, Corporate Secretary, Chief Legal Officer
• Andrew Grethlein,
  Executive Vice President, Chief Operating Officer
• Olivia Bloom,
  Chief Financial Officer, Executive Vice President - Finance, Treasurer
• Melissa Kelly Behrs,
  Executive Vice President, Chief Business Officer
• Dr. Aleksandra Rizo M.D., Ph.D.,
  Exec. VP & Chief Medical Officer
• Dr. Andrew J. Grethlein,
  Exec. VP & COO
• Melissa A. Kelly Behrs,
  Exec. VP of Bus. Operations & Chief Alliance Officer
• Olivia Kyusuk Bloom,
  Exec. VP of Fin., CFO & Treasurer
• Elizabeth O'Farrell,
  Independent Director
• Dawn Bir,
  Independent Director
• Karin Eastham,
  Lead Independent Director
• V. Bryan Lawlis,
  Independent Director
• Robert Spiegel,
  Independent Director
• Susan Molineaux,
  Independent Director
• Anil Kapur,
  Executive Vice President, Corporate Strategy and Chief Commercial Officer
• Edward E. Koval,
  Exec. VP & Chief Bus. Officer
• Anil Kapur,
  Chief Commercial Officer & Exec. VP of Corp. Strategy
• Stephen N. Rosenfield,
  Exec. VP, Chief Legal Officer & Corp. Sec.
• Shannon Odam,
  VP of HR
• Suzanne Messere,
  Head of Investor Relations & Corp. Communications
• Daniel Bradbury,
  Director
• Thomas Hofstaetter,
  Director
• Hoyoung Huh,
  Director
• James Ziegler,
  EVP, Chief Commercial Officer
• Gaurav Aggarwal,
  
• Calvin Harley,
  Chief Scientific Officer
• Graham K Cooper,
  EVP, Bus Dev & CFO
• Katharine E. Spink,
  VP Operations, Regen Med Progs
• Jane Lebkowski,
  VP Regenerative Medicine
• David Greenwood,
  SVP Corporate Development and
• Melanie I Nallicheri,
  SVP Corp Dev
• Alexander E Barkas,
  Director
• Charles J Homcy,
  Director
• Thomas Okarma,
  President and CEO
• Patrick J Zenner,
  Director
• Fabio M Benedetti,
  SVP, Chief Med Off, Oncology
• John Peter Walker,
  Director
• Alan Colowick,
  President, Oncology
• Robert B Stein,
  Director
• Stephen Michael Kelsey,
  EVP, CMO, Oncology
• Edward V Fritzky,
  Director
• Craig C Parker,
  SVP, Corporate Development
• David Earp,
  VP Intellectual Property
• Thomas Kiley,
  Director
• Bioscience Inc Merix,
  10% owner
• William Stempel,
  VP and General Counsel
• John F Mc Donald,
  
• Faye Feller,
  EVP, Chief Medical Officer
• Scott Alan Samuels,
  EVP, Chief Legal Officer
• Michelle Robertson,
  EVP, Chief Financial Officer